This article was originally published in The Gray Sheet
Executive SummaryPerforms first human implants in two patients of its Kinetra neurostimulator as part of a three-month safety and performance study, the firm says Aug 13. The study aims to support CE mark approval of the device and will involve 15-20 centers in Europe, Canada, and Australia. The Kinetra connects to two leads in the brain, eliminating the need to implant two separate neurostimulators in essential tremor or Parkinson's disease patients with bilateral symptoms, Medtronic claims
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.